CytomX Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

CytomX Therapeutics

04/03/2025 21:08

CytomX Therapeutics Inc CTMX.OQ CTMX.O is expected to show a fall in quarterly revenue when it reports  results on March 6 for the period ending December 31 2024

The South San Francisco California-based  company is expected to report a 27.0% decrease in revenue to $19.417 million from $26.61 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for CytomX Therapeutics Inc is for a loss of 20 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for CytomX Therapeutics Inc is $3.68​, above​ its last closing price of $0.65. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.16
-0.17
0.07
Beat
140.7
Jun. 30 2024
-0.12
-0.14
-0.08
Beat
44.2
Mar. 31 2024
-0.08
-0.08
0.17
Beat
305.2​
Dec. 31 2023
0.01
-0.03
0.01
Beat
135
​​Sep. 30 2023
-0.15
-0.19
0.04
Beat
121.2
Jun. 30 2023
-0.18
-0.20
-0.02
Beat
90.2​
Mar. 31 2023
-0.12
-0.11
-0.05
Beat
52.7
Dec. 31 2022
-0.17
-0.24
-0.43
Missed
-82.5

This summary was machine generated March 4 at 21:08 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)